Trials / Completed
CompletedNCT02166814
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 140 (actual)
- Sponsor
- Boryung Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of combination of Fimasartan/Rosuvastatin in comparison to each component administered alone in patients with essential hypertension and dyslipidemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fimasartan and Rosuvastatin | |
| DRUG | Fimasartan | |
| DRUG | Rosuvastatin |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2014-06-18
- Last updated
- 2017-02-13
Locations
26 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02166814. Inclusion in this directory is not an endorsement.